Cannabis Science Inc. is an emerging cannabis pharmaceutical company. Trading on the OTCBB, they are at the forefront of medical marijuana research and development. With headquarters in San Francisco, California, the company works with world authorities on phytocannabinoid science targeting critical illnesses. Phytocannabinoids - also called natural cannabinoids, herbal cannabinoids, and classical cannabinoids - are only known to occur naturally in significant quantity in the cannabis plant. They are concentrated in a viscous resin produced in glandular structures known as trichomes and are most prevalent in the flowers of the female plants.

Cannabis Science, Inc.’s dedication is to the creation of cannabis-based medicines. The company adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. They are working to create these medicines both with and without psychoactive properties as well as treat disease and the symptoms of disease

Last month, Cannabis Science reported that patent filings are expected for two of their key innovations. “The Drug Development Team members recognize the importance of having our first cannabis-based medicine covered, not just by one patent, but by two,” Dr. Mary J. Ruwart, Vice President, Research & Development explained. “A competitor can sometimes engineer a way around a single patent. Patenting both the manufacturing process as well as the delivery system virtually guarantees that our product will be immune to ‘invasion’ by a competing company.”

Today, Cannabis Science Inc. announced that they have retained Catalyst Xchange Corp. to provide them with investor relations services under an agreement dated June 30, 2009. Catalyst Xchange Corp. has their headquarters in London, Ontario. The investor relations company will provide a variety of promotional and investor relations services to Cannabis Science Inc. This will include assisting with the dissemination of news and information to the public, and initiating and maintaining contact with investors.